Sarilumab: patient-reported outcomes in rheumatoid arthritis
Chiara Crotti,1,2 Martina Biggioggero,3 Andrea Becciolini,3 Ennio Giulio Favalli3 1Department of Clinical Sciences and Health Community, University of Milan, 2Division of Rheumatology, Gaetano Pini Institute, Milan, Italy; 3Department of Rheumatology, Gaetano Pini Institute, Milan, Italy Abstract: I...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-08-01
|
| Series: | Patient Related Outcome Measures |
| Subjects: | |
| Online Access: | https://www.dovepress.com/sarilumab-patient-reported-outcomes-in-rheumatoid-arthritis-peer-reviewed-article-PROM |
| _version_ | 1811304430820130816 |
|---|---|
| author | Crotti C Biggioggero M Becciolini A Favalli EG |
| author_facet | Crotti C Biggioggero M Becciolini A Favalli EG |
| author_sort | Crotti C |
| collection | DOAJ |
| description | Chiara Crotti,1,2 Martina Biggioggero,3 Andrea Becciolini,3 Ennio Giulio Favalli3 1Department of Clinical Sciences and Health Community, University of Milan, 2Division of Rheumatology, Gaetano Pini Institute, Milan, Italy; 3Department of Rheumatology, Gaetano Pini Institute, Milan, Italy Abstract: In the last few decades, strategies for the management of rheumatoid arthritis (RA) have been increasingly oriented toward more comprehensive control of the disease, taking into account even RA extra-articular manifestations, comorbidities, and the patient’s perception about the disease. The need for improving the shared decision-making process suggested by European League Against Rheumatism recommendations is leading to an increasing interest in the role of patient-reported outcomes (PROs) beside the usual more objective criteria for defining clinical response based on disease-activity composite indices. Measurement of such PROs as pain or fatigue may be significantly influenced by mood disorders often complicating RA, the pathogenesis of which is deeply interconnected with phlogistic processes mediated by proinflammatory cytokines. IL6 is a pleiotropic mediator involved in neuroendocrine and neuropsychological processes, besides its well known effects on immune, cardiovascular, and metabolic systems. Therefore, there is a growing body of evidence about the efficacy of IL6 blockade in PRO improvement in RA patients. Sarilumab is a monoclonal antibody binding both soluble and membrane-bound IL6Rα, inhibiting the IL6-mediated signaling pathway with favorable efficacy and safety profile. This review analyzes the importance of PROs in strategies for the management of RA and the pathogenic mechanisms linking IL6 with the patient’s perception of the disease. Moreover, the main findings from sarilumab randomized controlled trials are summarized in detail, emphasizing the potential role of this IL6 blocker in the holistic treatment of RA. Keywords: rheumatoid arthritis, interleukin-6, sarilumab, patient reported outcome |
| first_indexed | 2024-04-13T08:07:08Z |
| format | Article |
| id | doaj.art-8d1fb2e536ff460b8333eb0bf91ea4a2 |
| institution | Directory Open Access Journal |
| issn | 1179-271X |
| language | English |
| last_indexed | 2024-04-13T08:07:08Z |
| publishDate | 2018-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Related Outcome Measures |
| spelling | doaj.art-8d1fb2e536ff460b8333eb0bf91ea4a22022-12-22T02:55:08ZengDove Medical PressPatient Related Outcome Measures1179-271X2018-08-01Volume 927528439944Sarilumab: patient-reported outcomes in rheumatoid arthritisCrotti CBiggioggero MBecciolini AFavalli EGChiara Crotti,1,2 Martina Biggioggero,3 Andrea Becciolini,3 Ennio Giulio Favalli3 1Department of Clinical Sciences and Health Community, University of Milan, 2Division of Rheumatology, Gaetano Pini Institute, Milan, Italy; 3Department of Rheumatology, Gaetano Pini Institute, Milan, Italy Abstract: In the last few decades, strategies for the management of rheumatoid arthritis (RA) have been increasingly oriented toward more comprehensive control of the disease, taking into account even RA extra-articular manifestations, comorbidities, and the patient’s perception about the disease. The need for improving the shared decision-making process suggested by European League Against Rheumatism recommendations is leading to an increasing interest in the role of patient-reported outcomes (PROs) beside the usual more objective criteria for defining clinical response based on disease-activity composite indices. Measurement of such PROs as pain or fatigue may be significantly influenced by mood disorders often complicating RA, the pathogenesis of which is deeply interconnected with phlogistic processes mediated by proinflammatory cytokines. IL6 is a pleiotropic mediator involved in neuroendocrine and neuropsychological processes, besides its well known effects on immune, cardiovascular, and metabolic systems. Therefore, there is a growing body of evidence about the efficacy of IL6 blockade in PRO improvement in RA patients. Sarilumab is a monoclonal antibody binding both soluble and membrane-bound IL6Rα, inhibiting the IL6-mediated signaling pathway with favorable efficacy and safety profile. This review analyzes the importance of PROs in strategies for the management of RA and the pathogenic mechanisms linking IL6 with the patient’s perception of the disease. Moreover, the main findings from sarilumab randomized controlled trials are summarized in detail, emphasizing the potential role of this IL6 blocker in the holistic treatment of RA. Keywords: rheumatoid arthritis, interleukin-6, sarilumab, patient reported outcomehttps://www.dovepress.com/sarilumab-patient-reported-outcomes-in-rheumatoid-arthritis-peer-reviewed-article-PROMrheumatoid arthritisinterleukin-6sarilumabpatient reported outcome |
| spellingShingle | Crotti C Biggioggero M Becciolini A Favalli EG Sarilumab: patient-reported outcomes in rheumatoid arthritis Patient Related Outcome Measures rheumatoid arthritis interleukin-6 sarilumab patient reported outcome |
| title | Sarilumab: patient-reported outcomes in rheumatoid arthritis |
| title_full | Sarilumab: patient-reported outcomes in rheumatoid arthritis |
| title_fullStr | Sarilumab: patient-reported outcomes in rheumatoid arthritis |
| title_full_unstemmed | Sarilumab: patient-reported outcomes in rheumatoid arthritis |
| title_short | Sarilumab: patient-reported outcomes in rheumatoid arthritis |
| title_sort | sarilumab patient reported outcomes in rheumatoid arthritis |
| topic | rheumatoid arthritis interleukin-6 sarilumab patient reported outcome |
| url | https://www.dovepress.com/sarilumab-patient-reported-outcomes-in-rheumatoid-arthritis-peer-reviewed-article-PROM |
| work_keys_str_mv | AT crottic sarilumabpatientreportedoutcomesinrheumatoidarthritis AT biggioggerom sarilumabpatientreportedoutcomesinrheumatoidarthritis AT becciolinia sarilumabpatientreportedoutcomesinrheumatoidarthritis AT favallieg sarilumabpatientreportedoutcomesinrheumatoidarthritis |